Clinical trials - Press Releases

Date	Title	Company
05-Apr-2022	FDA accepts Dupixent® (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis	Regeneron
05-Apr-2022	AI test could predict effective cancer drug combinations in less than two days	ICR
05-Apr-2022	Beckley Psytech announces dosing of first healthy volunteers in Phase 1 clinical trial assessing safety and pharmacokinetics of second innovative formulation of 5-MeO-DMT	Beckley Psytech
05-Apr-2022	FDA Grants Permission to Enroll up to 8 Additional Secondary Progressive Multiple Sclerosis (SPMS) Patients in the Expanded Access Program with Intranasal Foralumab	FDA
05-Apr-2022	CluePoints Continues Impressive Global Growth with Three New Senior Appointments	CluePoints
05-Apr-2022	Almac Group Clinical Supply And Commercial Solutions Support Agios' Road To FDA Approval	Almac Group
05-Apr-2022	AXON hires a Global Healthcare Insights and Strategy Lead	AXON
31-Mar-2022	Avance Clinical Announces New Office Opening in Melbourne	Avance Clinical
31-Mar-2022	TILT Biotherapeutics Announces Positive Update on its Phase 1 Immunotherapy Clinical Trials in Cancer	TILT Biotherapeutics
30-Mar-2022	Tower Cold Chain launches KTEvolution container for pharmaceutical transport	Tower Cold Chain
30-Mar-2022	New analysis shows that Kesimpta®▼ (ofatumumab)-treated adults with relapsing remitting multiple sclerosis (RRMS) are not at increased risk of severe COVID-19 infections	Novartis
29-Mar-2022	Freya Pharma Solutions secures US$8.5 million enabling the start of a pivotal phase 3 trial with Lybrido against Female Sexual Interest/Arousal Disorder (FSIAD)	Freya Pharma Solutions
29-Mar-2022	Bone Therapeutics to strategically focus on lead cell therapy product ALLOB	Bone Therapeutics
29-Mar-2022	Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis	Sanofi
28-Mar-2022	TolerogenixX Receives Approval to Start Phase IIb Trial for its Immune Tolerance-Inducing MIC-Lx Cell Therapy	TolerogenixX GmbH
25-Mar-2022	ICR welcomes FDA approval of ‘search and destroy’ treatment	The Institute of Cancer Research
25-Mar-2022	Tiziana Announces Initiation of Phase 1b Clinical Trial in Crohn’s Disease Patients to Evaluate Oral Capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody	Tiziana Life Sciences Ltd
25-Mar-2022	XFret Wins the 2021 Sustainability Award – Startup/Small Business Category	TIACA
25-Mar-2022	TIACA Announces the Take-Off of the BlueSky Program	TIACA
25-Mar-2022	Jazz Pharmaceuticals Announces Significant New Investment in UK Manufacturing	Jazz Pharmaceuticals